CAS: 162744-59-4; (4-Bromo-2,6-Difluorophenyl)Methanol

相似化合物

183065-68-1 537013-51-7 773134-11-5

上下游产品

CAS号183065-68-1 4-溴-2,6-二氟苯甲酸 | CAS号461-96-1 1-溴-3,5-二氟苯 | CAS号537013-51-7 4-溴-2,6-二氟苯甲醛 | CAS号228421-83-8 3,5-二氟-4-(羟基甲基)苯甲腈 | CAS号162744-60-7 5-溴-2-(溴甲基)-1,3-二氟苯 | CAS号917969-79-0 (3,5-二氟-4-(羟甲基)苯基)硼酸

4-溴-2,6-二氟苯甲酸置于甲醇体系中,用 四氢呋喃 用作溶剂,化学反应 16.0H,以to Yield A White Solid Of (4-Bromo-2,6-Difluorophenyl)Methanol (4.5 G,20.02 Mmol,95.2% Yield),Which的收率获得4-溴-2,6-二氟苯甲醇
参考文献:Novel Compounds As Rearranged During Transfection (Ret) Inhibitors
标题:Novel Compounds As Rearranged During Transfection (Ret) Inhibitors
摘要:本发明涉及一种新型化合物,其为重排转录因子(ret)激酶的抑制剂,以及含有它们的制药组合物,其制备过程和其在治疗中的使用,单独或联合使用,用于正常化胃肠敏感性,运动性和/或分泌以及腹部紊乱或疾病和/或与ret功能障碍相关的治疗或调节ret活性可能具有治疗效益的疾病,包括但不限于所有分类的肠易激综合症(ibs),包括腹泻型,便秘型或交替排便模式,功能性腹胀,功能性便秘,功能性腹泻,未特指的功能性肠道疾病,功能性腹痛综合征,慢性特发性便秘,功能性食管障碍,功能性胃十二指肠障碍,功能性肛门疼痛,炎症性肠病,非小细胞肺癌,肝细胞癌,结直肠癌,髓样甲状腺癌,滤泡性甲状腺癌,间变性甲状腺癌,乳头状甲状腺癌,脑肿瘤,腹腔癌,实体肿瘤,其他肺癌,头颈癌,胶质瘤,神经母细胞瘤,Von Hippel-Lindau综合征和肾肿瘤,乳腺癌,输卵管癌,卵巢癌,移行细胞癌,前列腺癌,食管和胃食管连接处的癌症,胆道癌,腺癌以及任何ret激酶活性增加的恶性肿瘤.

专利信息

专利号:US-9540371-B2
优先权日:2013-04-29
标 题:Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
发明人：LINDSLEY CRAIG W; CONN P JEFFREY; STAUFFER SHAUN R; PANARESE JOSEPH DAVID
权利人:UNIV VANDERBILT
摘要:In one aspect, the invention relates to 3-benzylquinazolin-4(3H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 1 (mAChR M 1 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. Exemplary 3-benzylquinazolin-4(3H)-one compounds include compounds of formula (I):

专利号:WO-2025096495-A1
优先权日:2023-10-30
标 题 :Aryl fluorosulfate-based inhibitors as novel antitubercular agents
发明人：YANG BAIYUAN; MCNAMARA CASE W; CHATTERJEE ARNAB K; PETRASSI H MICHAEL; SHARPLESS K BARRY; QIN BO; SUKHEJA PARIDHI; LOVE MELISSA; WOODS ASHLEY; LIU DONGDONG
权利人:SCRIPPS RESEARCH INST
摘要:The disclosure provides the identification and development of a first-in-class, small-molecule inhibitor (Compound 95) of Polyketide synthase 13 (Pks13), a critical node in cell wall biosynthesis for Mycobacterium tuberculosis (Mtb). Cell wall inhibitors are a critical component of TB treatment. Uniquely, the Compound 95 series has been shown to form a covalent adduct with serine residue 801 in the acyltransferase (AT) domain of Pks13. The inhibition of the Pks13 AT domain ultimately leads to disruption of mycolic acid synthesis, which is an essential component of the mycobacterial cell wall. While Pks13 is recognized as a high-value drug target, there are no Pks13 inhibitors in development and Compound 95 represents a new class of inhibitors for TB treatment.